Read This Before You Play a Single One of the Biotechs Fighting COVID-19

D.R. Barton, Jr.

Georgia, South Carolina, and Florida have announced that they are loosening quarantine restrictions; at least 13 more states have announced plans or "roadmaps" to do more or less the same thing.

There's an urgent desire to get "back to normal" as quickly as possible because the social and economic devastation – record unemployment, more than 55,300 deaths, massive lockdowns, shrinking GDP, and of course the virus itself – of the coronavirus pandemic has been so profound.

And this has all happened in a little more than a month. People are understandably anxious to put all this behind them, myself very much included.

But the stakes of "normalcy" are higher than we're being told. The successful reemergence of people into the world will require far more than just repeated reminders to wash your hands and not touch your face.

Social distancing and limited interaction can slow the spread; there's mounting evidence in the United States and other countries that we've done precisely that. But it's far from clear how much those actions could really prevent widespread illness as lockdowns ease and stay-at-home orders are lifted.

Because it's very likely that we won't be truly "safe" until a proven treatment and effective vaccine are available.

The more we learn about this virus, the more we're aware of why its ongoing impact, and the "right" way to reopen the economy, remain so uncertain.

Here's what we do know:

1. It's highly contagious. The virus seems to be more robust than many similar viruses – it lives for hours on droplets in the air and for days on most surfaces. Asymptomatic people carry and transmit it. And since it is a "novel" coronavirus, meaning this is the first time it has circulated among humans, we basically have no preexisting defenses.

2. The virus is dreadfully and inexplicably selective. This means that similar people can contract the virus and one will have no symptoms, another will have mild symptoms, and yet another will have severe symptoms up to and including death. We know that there are risk factors for severity, like age, obesity, and preexisting conditions. But even within those subgroups, the virus acts very differently from patient to patient.

3. Help from a vaccine that would immunize us is still a long way off. From the start, the "best-case scenario" estimate was 18 months for a vaccine. That leaves 16.5 months to go, but only if everything goes right, and we witness the fastest outcome in medical history.

4. Right now, we have no proven therapeutic treatment for COVID-19 patients. This one is If you contract this virus, medical professionals can only treat symptoms and offer supportive care as the body attempts to rid itself of the virus. There is as yet no proven way to treat the underlying virus.

And that is precisely what we're going to talk about today. There's a tremendous amount of buzz and hype surrounding potential coronavirus therapies and vaccines right now.

What you're about to see has generated total gains of 1,359% since October. It's fast and it's perfect for right now. This is how you can take back your wealth, one day at a time. It all starts tomorrow, April 29… But you must RSVP now…

This buzz has precipitated what I call the "Gilead Effect," where the $100 billion biotech helped lead markets higher and lower on what were essentially rumors and fragmentary reports on its progress toward a COVID-19 treatment.

In other words, a "Reality Gap" – with profit and pitfall potential – has opened up here, centered on the perception of the state of play in coronavirus treatments.

Now, it's true there are a number of potential treatments for COVID-19 currently in trials. But there is as yet no silver bullet.

Nevertheless, pharmaceutical companies really do have a chance to save the world here.

I'm going to show you what's really going on here; every investor needs to be aware of the truth because the stakes are so high. Here's what the data says about the top contenders…

D.R. Barton, Jr.

About the Author

Browse D.R.'s articles | View D.R.'s research services

D.R. Barton, Jr., Technical Trading Specialist for Money Map Press, is a world-renowned authority on technical trading with 25 years of experience. He spent the first part of his career as a chemical engineer with DuPont. During this time, he researched and developed the trading secrets that led to his first successful research service. Thanks to the wealth he was able to create for himself and his followers, D.R. retired early to pursue his passion for investing and showing fellow investors how to build toward financial freedom.

… Read full bio